| MIRDAMETINIB | None | ||
| 1MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| GOMEKLI is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. | |||
|
Yes
| |||
| GOMEKLI | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||||||||
| ************ ** *********** **** **** ** ** *-((*)-*,*-****************)-*,*-********-*-(*-******-*-****-***********)-********* *** **** ******* | *********** ****** ** *** ********* *-((*)-*,*-****************)-*,*-********-*-(*-******-*-****-***********)-********* *** **** ******* | ******* ** ******** ***************** **** *-((*)-*,*-****************)-*,*-********-*-(*-******-*-***************)-********* | *********** ************ ** *-((*)-*,*-****************)-*,*-********-*-(*-******-*-****-***********)-********* *** **** ******* | ***-****** ****** ** ************ | ************ ********* | ********* ** ***************** **** * (***) ********** ********* ************* (**) ** ********* ******** **** ************ | ************ ********* | ************ ********* | ********* ** ***************** **** * (***) ********** ********* ************* (**) ** ********* ******** **** ************ | ****** ***** ** ************ | ******* ** ******** ***************** **** * **** *-((*))-*,*-****************)-*,*-********-*-(*-******-*-***************)-********* | *********** ************ ** *-((*)-*,*-****************)-*,*-********-*-(*-******-*-****-***********)-********* *** **** ******* | ************ ********* | ************ ********* | ***-****** ****** ** ************ | ********* ** ***************** **** * (***) ********** ********* ************* (**) ** ********* ******** **** ************ | ************ ********* | *********** ************ ** *-((*)-*,*-****************)-*,*-********-*-(*-******-*-****-***********)-********* *** **** ******* | ************ ********* |
| MIRDAMETINIB | None | ||
| 1MG, 2MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| GOMEKLI is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. | |||
|
Yes
| |||
| GOMEKLI | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||||||||||||
| ************ ** *********** **** **** ** ** *-((*)-*,*-****************)-*,*-********-*-(*-******-*-****-***********)-********* *** **** ******* | *********** ****** ** *** ********* *-((*)-*,*-****************)-*,*-********-*-(*-******-*-****-***********)-********* *** **** ******* | ******* ** ******** ***************** **** *-((*)-*,*-****************)-*,*-********-*-(*-******-*-***************)-********* | ***-****** ****** ** ************ | ************ ********* | ********* ** ***************** **** * (***) ********** ********* ************* (**) ** ********* ******** **** ************ | ************ ********* | ************ ********* | ********* ** ***************** **** * (***) ********** ********* ************* (**) ** ********* ******** **** ************ | ****** ***** ** ************ | ******* ** ******** ***************** **** * **** *-((*))-*,*-****************)-*,*-********-*-(*-******-*-***************)-********* | ************ ********* | ************ ********* | ***-****** ****** ** ************ | *********** ****** ** *** ********* *-((*)-*,*-****************)-*,*-********-*-(*-******-*-****-***********)-********* *** **** ******* | ********* ** ***************** **** * (***) ********** ********* ************* (**) ** ********* ******** **** ************ | ************ ********* | ****** ***** ** ************ | ************ ********* |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|